Please assess the completion status of the following clinical trial:

Trial Title: One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Moderate, non-fistulizing Crohn's disease in the ileum and/or colon prior to randomization; and a SES-CD score of ≥7 (confirmed by centralized endoscopy reading).~* During the screening period, the participant will need to have certain average daily scores for abdominal pain and average number of liquid/very soft stools.~Major Exclusion Criteria:~* Pregnant or lactating females. Females of childbearing (reproductive) potential must have a negative serum pregnancy test at screening and agree to use a highly effective method(s) of contraception throughout their participation in the study. Diagnosis of ulcerative or indeterminate colitis.~* Diagnosis of Celiac Disease.~* Bowel surgery within 12 weeks prior to screening and/or has surgery planned or deemed likely for Crohn's disease during the study period.~* Presence of an ileostomy or colostomy.~* Known fixed symptomatic stenosis/stricture of the small or large bowel.~* Had more than one segmental colonic resection.~* Had more than 3 small bowel resections or symptoms associated with short bowel syndrome.~* Current evidence of peritonitis.~* History or evidence of colonic mucosal dysplasia.~* History or evidence of adenomatous colonic polyps that have not been removed.~* Unwilling to be tapered off corticosteroids by Week 8 or the participant is known by the Investigator to be steroid-dependent.~* Has used a biologic within 12 weeks of randomization.~* Used cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or similar drugs within 8 weeks prior to randomization.~* Had rectal administration of 5-aminosalicylic acid (5-ASA) or corticosteroid enemas/foams/ suppositories within 2 weeks prior to screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin EIR 800 mg (Type: EXPERIMENTAL): Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).